FIELD: pharmachology.
SUBSTANCE: invention describes new compounds with general formula (I-c)
Where R1 is a radical (d-1) or (d-2) (radical values are given in the invention formula) and pharmaceutical composition containing them. The described compounds are the hepatitis C inhibitors and can be used in medicine.
EFFECT: enhanced hepatitis C inhibition.
5 cl, 1 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HEPATITIS C VIRUS MACROCYCLIC INHIBITORS | 2006 |
|
RU2486189C2 |
| MACROCYCLIC HEPATITIS C VIRUS INIHBITORS | 2006 |
|
RU2437886C2 |
| MACROCYCLIC HEPATITIS C INHIBITORS | 2006 |
|
RU2436787C2 |
| MACROCYCLIC PHENYLCARBAMATES INHIBITING HCV | 2008 |
|
RU2490261C2 |
| MACROCYCLIC HEPATITIS TYPE C VIRUS INHIBITORS | 2006 |
|
RU2419619C2 |
| PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | 2008 |
|
RU2481340C2 |
| DIARYL ETHERS | 2010 |
|
RU2528231C2 |
| MACROCYCLIC INDOLE DERIVATIVES, APPLICABLE AS INHIBITORS OF HEPATITIS C VIRUS | 2009 |
|
RU2518471C2 |
| PHENYLETHYNYL DERIVATIVES AS HEPATITIS C VIRUS INHIBITORS | 2010 |
|
RU2538507C2 |
| 1,5,6-SUBSTITUTED 2-OXO-3-CYANO-1,6A-DIAZATETRAHYDROFLUORANTHENES | 2006 |
|
RU2389730C2 |
Authors
Dates
2012-02-10—Published
2006-07-28—Filed